Advanced Diagnostics And Personalized Therapies Will Expand Global Markets

Published
06 Aug 24
Updated
14 Aug 25
AnalystConsensusTarget's Fair Value
US$245.95
14.2% undervalued intrinsic discount
14 Aug
US$210.93
Loading
1Y
-21.7%
7D
5.2%

Author's Valuation

US$246.0

14.2% undervalued intrinsic discount

AnalystConsensusTarget Fair Value

Shared on07 May 25
Fair value Decreased 0.41%

Shared on30 Apr 25
Fair value Decreased 2.27%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on23 Apr 25
Fair value Decreased 0.69%

AnalystConsensusTarget has increased revenue growth from 5.2% to 6.1%.

Shared on16 Apr 25
Fair value Decreased 2.26%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on09 Apr 25
Fair value Decreased 1.45%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on02 Apr 25
Fair value Decreased 0.76%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on26 Mar 25
Fair value Decreased 0.23%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on19 Mar 25
Fair value Decreased 0.31%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on10 Mar 25
Fair value Increased 8.30%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.